-
公开(公告)号：US20240327408A1
公开(公告)日：2024-10-03
申请号：US18579501
申请日：2022-07-14
发明人： Haiying SUN , Yibei XIAO , Yuantao FU , Rongliang TAN , Guangjun XIE , Jinxin JIANG , Yinan YUAN
IPC分类号： C07D471/14 , A61K31/4375 , A61K31/444 , A61K31/4745 , A61K31/519 , A61P35/02 , C07D471/04 , C07D491/147 , C07D495/14 , C07D513/14
CPC分类号： C07D471/14 , A61K31/4375 , A61K31/444 , A61K31/4745 , A61K31/519 , A61P35/02 , C07D471/04 , C07D491/147 , C07D495/14 , C07D513/14
摘要： The present invention is related to compounds of formula I containing a tetrahydronaphthyridinone or tetrahydropyridopyrimidinone skeleton and preparation methods therefor. It has been experimentally verified that the compounds containing a tetrahydronaphthyridinone or tetrahydropyridopyrimidinone skeleton have significant agonistic effects on caseinolytic protease P (ClpP), and can be applied in the treatment of various cancers.
-
公开(公告)号：US20240280493A1
公开(公告)日：2024-08-22
申请号：US18570741
申请日：2023-02-09
发明人： Wenyuan LIU , Lingfei HAN , Feng FENG
CPC分类号： G01N21/658 , B22F1/054 , B22F1/102 , B22F1/145 , B22F9/24 , G01N33/5067 , G01N33/54346 , B22F2301/255 , B22F2304/054 , B22F2998/10 , B22F2999/00
摘要： A cell-based sensor based on surface-enhanced Raman scattering and an application thereof. The cell-based sensor is established by guiding a surface-enhanced Raman scattering probe into a human liver cell line; the surface-enhanced Raman scattering probe is prepared by using a gold nanoparticle as a testing substrate, a gene damage effector molecule antibody as a recognition unit, a Raman molecule as a reporting unit, SH-PEG-NH2 as a stable chain and a cell-penetrating peptide as an auxiliary penetration unit; and the cell-based sensor is exposed to various drug impurities, a Raman signal is detected, and a type and a level of the genotoxic impurities are assessed.
-
公开(公告)号：US11541032B2
公开(公告)日：2023-01-03
申请号：US16960226
申请日：2019-11-22
发明人： Haiping Hao , Hong Wang , Jiyu Zhou , Guangji Wang , Shuang Cui , Xiaojie Pan , Yitong Guo , Ningning Huang
IPC分类号： A61K31/357 , A61K31/201 , A61K31/42 , A61K31/55 , A61K31/575
摘要： A composition containing SUMO inhibitor, and belongs to the technical field of medicine includes FXR agonist and SUMO inhibitor. In activated hepatic stellate cells, the FXR agonist does not have an effect in inhibiting the activation of hepatic stellate cells. After the FXR agonist and the SUMO inhibitor are compounded according to the present invention, the activation of hepatic stellate cells can also be inhibited for those cells under activated state. Of note, the hepatic stellate cells of an individual with hepatic fibrosis symptoms have been in an activated state, therefore a good anti-fibrotic effect cannot be achieved by using the FXR agonist alone.
-
公开(公告)号：US20220389025A1
公开(公告)日：2022-12-08
申请号：US17761252
申请日：2020-09-21
申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences , China Pharmaceutical University
发明人： Wenhu DUAN , Meiyu GENG , Huibin ZHANG , Zuoquan XIE , Jinpei ZHOU , Yifei YANG , Xiyuan WANG , Xiaojun YANG , Yan ZHANG , Zhaoxue HU , Jian DING
IPC分类号： C07D491/048 , C07D519/00 , A61P35/00
摘要： Provided are a heterocyclic amide compound of general formula (I), a pharmaceutically acceptable salt thereof and a preparation method therefor, and the use of the compound in the preparation of a drug for treating diseases related to the activity of STING, in the preparation of an immunologic adjuvant, and in the preparation of a drug for activating STING.
-
5.发明申请公开(公告)号：US20220152027A1
公开(公告)日：2022-05-19
申请号：US17434353
申请日：2019-03-22
发明人： Qi Dong YOU , Xiaoke GUO , Weilin CHEN , Dongdong LI , Jing GU , Jun XU , Xin CHEN , Zhengyu JIANG , Xiaoli XU
IPC分类号： A61K31/517 , A61P35/00 , A61K31/506 , A61K31/5355
摘要： The present disclosure discloses a WDR5 protein-protein interaction inhibitor, including a compound having a structure represented by general formula (I). Experiments show that the inhibitor acts on a WDR5 protein and an interacting protein thereof including, but not limited to, MLL, selectively inhibits the proliferation of leukemia cells, and inhibits the methylation of H3K4 and the expression of downstream Hox/Meis-1 gene at the cellular level. The present disclosure also discloses a method for preparing the inhibitor and use thereof in the preparation of a drug for treating acute leukemia and other related diseases.
-
公开(公告)号：US20210338695A1
公开(公告)日：2021-11-04
申请号：US15734960
申请日：2019-09-04
发明人： Qidong YOU , Zhengyu JIANG , Yan WANG , Yuhui JIN , Mengchen LU , Xiaoli XU , Xiaoke GUO
IPC分类号： A61K31/655 , A61K47/55 , A61K47/54 , A61K31/506 , A61P35/02 , A61K41/00
摘要： It discloses a proteolysis targeting chimeric molecule, a preparation method and an application thereof. The proteolysis targeting chimeric molecule provided by the disclosure can inhibit the expression of BCR-ABL and/or CRBN protein in BCR-ABL and/or CRBN positive leukemia K562 cells to varying degrees, and thus can be used to prepare drugs for treating BCR-ABL and/or CRBN positive leukemia, wherein the proteolysis targeting chimeric molecule with n=3 has excellent photo-isomerization activity, and can be used in preparation of the reagents or drugs for light-regulated degradation of BCR-ABL and/or CRBN protein. The disclosure also provides a method for synthesizing the series of proteolysis targeting chimeric molecules.
-
公开(公告)号：US20210220288A1
公开(公告)日：2021-07-22
申请号：US16755306
申请日：2018-11-29
发明人： Jianping ZHOU , Yang DING , Huaqing ZHANG
IPC分类号： A61K9/51 , A61K31/445 , A61K31/12 , A61K31/4748 , A61K31/7105 , A61K38/08 , A61K31/13 , A61K31/5415
摘要： The present invention belongs to the field of medicinal preparations, and more particularly relates to preparation and application of a natural nanoparticle-drug composition for Alzheimer's disease (AD) therapy. A technical problem solved by the present invention is to construct the natural nanoparticle-drug composition by extracting natural lipoprotein nanoparticles and recombining AD treatment drugs to achieve the purpose of anti-AD combination treatment. The present invention provides a prescription composition, a preparation process, property evaluation and application of the natural nanoparticle-drug composition, the natural nanoparticle-drug composition is administered in modes of intravenous injection, oral administration, nasal administration and the like, new ideas and new technologies are provided for research and development of new AD drugs, and important research value and clinical research prospects are achieved.
-
公开(公告)号：US20210169779A1
公开(公告)日：2021-06-10
申请号：US16769851
申请日：2018-05-08
发明人： Ninghua TAN , Zhen WANG , Kai TANG
IPC分类号： A61K9/00 , A61K31/7028 , A61P27/04 , A61P9/10
摘要： It discloses an ophthalmic pharmaceutical preparation as well as a preparation method and application thereof. Components of the pharmaceutical preparation are easy to obtain and are from a panax notoginseng extract. The pharmaceutical preparation is a natural traditional Chinese medicine preparation and contains the following components with a total of 45 to 95%: a notoginsenoside R1, a notoginsenoside R2, a ginsenoside Rg1, a ginsenoside Rg2, a ginsenoside Re, a ginsenoside Rb1, a ginsenoside Rb2, a ginsenoside Rd, a ginsenoside Rf, a ginsenoside Rc, a ginsenoside Rh1 and a gypenoside IX. The extract can be made into eye drops, eye ointments, eye pads, eye cream and other various dosage forms according to clinical demands.
-
公开(公告)号：US20210162041A1
公开(公告)日：2021-06-03
申请号：US17052360
申请日：2019-04-19
发明人： Wenbing YAO , Hong TIAN , Yi XU , Yu HE , Xiangdong GAO
IPC分类号： A61K39/385 , A61K39/00 , C07K7/08
摘要： A helper epitope peptide is obtained by means of replacing one or two amino acid residues in the helper T cell epitope PADRE with 4-nitrophenylalanine. The helper epitope peptide is effective for enhancing the immunogenicity of an antigen or antigenic epitope or for preparing or constructing a vaccine, and a fusion antigen formed by connecting the helper epitope peptide to an antigen or an antigenic epitope.
-
公开(公告)号：US11014895B2
公开(公告)日：2021-05-25
申请号：US16477779
申请日：2018-01-01
发明人： Sheng Jiang , Zhengchao Tu , Haiping Hao , Hequan Yao , Yatao Qiu , Yiwu Yao , Dong Chen
IPC分类号： C07D261/18 , C07D271/04 , C07D307/68 , C07D407/12 , C07D409/12 , C07D413/12
摘要： A heterocyclic urea compound, and specifically discloses an indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound, which solves the problems of weak curative effect and larger toxic and side effects of existing immunological therapy drugs. The invention further provides a preparation method for an indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound, and an application of the indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound or a pharmaceutically acceptable salt thereof in preparing drugs for treating or preventing tumors.
-
-
-
-
-
-
-
-
-
搜索结果
70 条记录 (耗时 0.023 秒)
